Phase I study of STX 64 (667 Coumate) in breast cancer patients: the first study of a steroid sulfatase inhibitor

Tools

Stanway, Susannah J and Purohit, Atul and Woo, L W Lawrence and Sufi, Saulat and Vigushin, David and Ward, Rebecca and Wilson, Richard H and Stanczyk, Frank Z and Dobbs, Nicola and Kulinskaya, Elena and Elliott, Moira and Potter, Barry V L and Reed, Michael J and Coombes, R Charles (2006) Phase I study of STX 64 (667 Coumate) in breast cancer patients: the first study of a steroid sulfatase inhibitor. Clinical Cancer Research, 12 (5). pp. 1585-92. ISSN 1078-0432 (https://doi.org/10.1158/1078-0432.CCR-05-1996)

Full text not available in this repository.Request a copy

Abstract

Inhibition of steroid sulfatase (STS), the enzyme responsible for the hydrolysis of steroid sulfates, represents a potential novel treatment for postmenopausal women with hormone-dependent breast cancer. Estrone and DHEA are formed by this sulfatase pathway and can be converted to steroids (estradiol and androstenediol, respectively), which have potent estrogenic properties.

ORCID iDs

Stanway, Susannah J, Purohit, Atul, Woo, L W Lawrence, Sufi, Saulat, Vigushin, David, Ward, Rebecca, Wilson, Richard H, Stanczyk, Frank Z, Dobbs, Nicola, Kulinskaya, Elena, Elliott, Moira ORCID logoORCID: https://orcid.org/0000-0002-9964-5671, Potter, Barry V L, Reed, Michael J and Coombes, R Charles;
CORE (COnnecting REpositories)